‘Boring’ AstraZeneca & GSK still offer upside July 29, 2015/ Jamie Legg / News Hugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline. Link
Can Oil Majors Remain Investible As The World Transitions To Net Zero?Hugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline.
Trium Capital PM on engaging with companies: ‘We are not trying to be a loud activist’Hugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline.
Taking The Plunge – The Actions Needed to Halt ‘Disturbing’ Biodiversity LossHugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline.